驱动基因突变非小细胞肺癌免疫治疗的研究进展  

Advances of Immunotherapy for Non-small Cell Lung Cancer with Driver Gene Mutations

作　　者：苏春霞[1] 俞昕 SU Chunxia;YU Xin(Department of Oncology,Shanghai Pulmonary Hospital&Thoracic Cancer Institute,Tongji University School of Medicine,Shanghai 200433,China)

机构地区：[1]同济大学附属上海市肺科医院肿瘤科,上海200433

出　　处：《肿瘤防治研究》2023年第1期1-5,共5页Cancer Research on Prevention and Treatment

摘　　要：随着肺癌靶点的发现和药物研发,靶向治疗改善了驱动基因突变非小细胞肺癌(NSCLC)的临床预后。同时,免疫检查点抑制剂在驱动基因阴性NSCLC中也取得了良好的疗效。虽然部分驱动基因突变患者从对应靶向治疗中明显获益,但对免疫治疗反应欠佳。在大部分免疫治疗临床研究和日常实践中,EGFR/ALK等驱动基因突变阳性的NSCLC患者也被排除在外,或者仅占少数。免疫治疗如何应用于驱动基因突变患者,以及如何在靶向治疗、化疗及免疫治疗中选择最佳治疗方案,制定最优治疗策略,对改善晚期驱动基因突变NSCLC患者预后至关重要。本文对不同基因突变肿瘤免疫微环境的特点及免疫治疗在不同基因突变的NSCLC患者中的应用进行简要综述。With the discovery of lung cancer targets and drug development,targeted therapy has improved the clinical prognosis of non-small cell lung cancer(NSCLC)with driver gene mutations.Immune checkpoint inhibitors(ICIs)have shown good efficacy in driver gene-negative NSCLC.Although some patients with driver gene mutations benefited significantly from the corresponding targeted therapy,they did not respond well to immunotherapy.In most clinical trials and daily practice,patients with NSCLC and driver gene mutations such as EGFR and ALK are excluded or only account for a minority of patients.Applying immunotherapy to patients with driver gene mutations,selecting the best treatment regimens among targeted therapy,chemotherapy,and immunotherapy,and formulating the optimal treatment strategy are crucial to improve the prognosis of patients with advanced NSCLC and driver gene mutations.This paper reviews the characteristics of tumor immune microenvironment with different driver gene mutations and the application of immunotherapy for patients with NSCLC and different driver gene mutations.

关 键 词：非小细胞肺癌 驱动基因突变 免疫治疗 

分 类 号：R734.2[医药卫生—肿瘤]